K., Anamika, F., Singla, A., Jain, P., & Jain, R
doi: 10.1146/annurev-pharmtox-010818021856 89 PiotrowskaMSwierczynskiMFichnaJPiechota-PolanczykA
Its shares fell nearly 50 percent in 2025 and are down a further 15 percent this year, while the company now expects sales and profit to decline 5 percent13 percent in 2026, mainly because of US pricing pressure and loss of semaglutide exclusivity in markets such as Canada and China, according to CNBC
Parting thoughts History offers a cautionary note
Red Flags for Low Quality Be wary of providers that charge suspiciously low prices (under $150 monthly, suggesting corner-cutting), wont disclose which pharmacy compounds their medication, make unrealistic effectiveness claims, dont require medical consultation before prescribing, operate without licensed healthcare providers, or ship from outside the United States